Screener
Recursion Pharmaceuticals, Inc. RXRX Accounts Payable Current
Accounts Payable Current at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Recursion Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 6:32 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001601830-26-000098
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Total assets | $1,212,668 | $1,474,130 |
| Liabilities and stockholders’ equity | ||
| Current liabilities | ||
| Accounts payable | $12,672 | $18,118 |
| Accrued expenses and other liabilities | 56,936 | 70,230 |
| Unearned revenue | 27,586 | 37,605 |
| Operating lease liabilities | 13,249 | 12,663 |
| Notes payable and financing lease liabilities | 9,443 | 9,091 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Recursion Pharmaceuticals, Inc.'s accounts payable current?
- Recursion Pharmaceuticals, Inc. (RXRX) reported accounts payable current of $12.67M in Q2 2026.
- How has Recursion Pharmaceuticals, Inc.'s accounts payable current changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s accounts payable current decreased by 34.4% year-over-year, from $19.31M to $12.67M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s accounts payable current?
- Over 5 years (2020 to 2025), Recursion Pharmaceuticals, Inc.'s accounts payable current has grown at a 76.0% compound annual growth rate (CAGR), from $1.07M to $18.12M.
- What does accounts payable current mean?
- Accounts Payable Current as reported by Recursion Pharmaceuticals, Inc. Class A Common Stock.
Ask your AI about Recursion Pharmaceuticals, Inc.'s accounts payable current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude